cro.directory
← Compare landing

Cyagen Biosciences vs GemPharmatech

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/cyagen/gempharmatech

CategoryCyagen BiosciencesGemPharmatech
Listed sitecrocro
SummaryCyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical drug discovery, with specialized platforms including HUGO-GT™ and HUGO-Ab™ for humanized target validation and antibody screening.GemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.
Services
  • Specialized & Large-Animal Models
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • Translational Research
  • Immunology & Inflammation Services
  • Virology Services
  • Specialized & Large-Animal Models
  • In Vivo PK / PD Studies
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • Target Identification & Validation
Modalities
  • Biologics (Monoclonal Antibodies)
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
  • Biologics (Monoclonal Antibodies)
Indications
  • Oncology
  • Immunology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Ophthalmology
  • Oncology
  • Metabolic
  • Cardiovascular
  • Immunology
  • Neurology
  • Infectious Disease
  • Rare Disease
Locations
  • Headquarters, Santa Clara, California, United States
  • Headquarters, Jiangsu, China
Certifications
  • AAALAC International · Identifier: AAALAC-accredited facilities
Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.